The vaccines target Carcinoembryonic Antigen (CEA) and Mucin 1 (MUC-1), proteins commonly overexpressed in adenocarcinomas, and were combined with sargramostim (GM-CSF) to enhance immune response without significant toxicity [22, 23]. This evidence concerns the gene MUC1 and adenocarcinoma.